Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Thomas Amatruda"'
Autor:
Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert
Publikováno v:
EBioMedicine, Vol 47, Iss , Pp 89-97 (2019)
Background: Talimogene laherparepvec (T-VEC) is an intralesionally delivered, modified herpes simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission of T-VEC was systematically evaluated during and aft
Externí odkaz:
https://doaj.org/article/c636d98304cf434ca98de4705a2ed3ba
Autor:
Matthew C Perez, Jonathan S Zager, Thomas Amatruda, Robert Conry, Charlotte Ariyan, Anupam Desai, John M Kirkwood, Sheryl Treichel, David Cohan, Leon Raskin
Publikováno v:
Melanoma Management, Vol 6, Iss 2 (2019)
Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. Materials & methods: A chart review was cond
Externí odkaz:
https://doaj.org/article/c8385458321f4b77a503e93ba40e9715
Publikováno v:
Journal of Clinical Oncology. 40:e15038-e15038
e15038 Background: We convened a molecular tumor board in an oncology specialty practice of 60 oncologists. Monthly meetings were held remotely, with participation of molecular oncology experts from Caris Life Sciences. Cases were selected for MTB by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e637d4197b8b38d6d8d8217d6574d7c2
https://doi.org/10.1200/jco.2022.40.16_suppl.e15038
https://doi.org/10.1200/jco.2022.40.16_suppl.e15038
Autor:
Andrew N. Cornforth, Carol DePriest, Gabriel Nistor, Edward F. McClay, Robert O. Dillman, Thomas Amatruda
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’s mutanome, autologous tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc0994185ca1e630b3233558df4558be
http://link.springer.com/article/10.1186/s40425-018-0330-1
http://link.springer.com/article/10.1186/s40425-018-0330-1
Autor:
Ananta S Bangdiwala, Emil Lou, Kathryn Beal, Thomas Amatruda, John P. Kirkpatrick, Steve Braunstein, Laurie E. Gaspar, David Roberge, Penny K. Sneed, James B. Yu, Veronica Chiang, Laura Masucci, Wen Jiang, Paul W. Sperduto, William Sperduto, Helen A. Shih, Jason K. Molitoris, Norman Yeh, Daniel A. Wattson, Paul D. Brown, Minesh P. Mehta, Natalie A. Lockney, Ryan Shanley
Publikováno v:
International journal of radiation oncology, biology, physics, vol 99, iss 4
PurposeTo update the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for a markedly heterogeneous patient population, patients with melanoma and brain metastases, using a larger, more current cohort, including molecular markers.MethodsThe or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7ba536449909887f58df668655f80d1
https://doi.org/10.1016/j.ijrobp.2017.06.2454
https://doi.org/10.1016/j.ijrobp.2017.06.2454
The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases
Autor:
Thomas Amatruda, Ananta S Bangdiwala, William Sperduto, Kathryn Beal, John P. Kirkpatrick, Ryan Shanley, Norman Yeh, Emil Lou, Penny K. Sneed, Laurie E. Gaspar, Jason K. Molitoris, Helen A. Shih, Daniel A. Wattson, James B. Yu, David Roberge, Veronica Chiang, Laura Masucci, Wen Jiang, Natalie A. Lockney, Paul D. Brown, Minesh P. Mehta, Steve Braunstein, Paul W. Sperduto
Publikováno v:
International journal of radiation oncology, biology, physics, vol 98, iss 5
PurposeBrain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients.Methods and materialsWe created a retrospective multi-institutional database of 823 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d33d49ea1224f92dbc4b86beb0edde4f
https://doi.org/10.1016/j.ijrobp.2017.03.030
https://doi.org/10.1016/j.ijrobp.2017.03.030
Autor:
Janice M. Mehnert, Cheng-Pang Hsu, Thomas Amatruda, John Walker, Jonathan S. Zager, Cheryl A. Pickett, John Nemunaitis, Robert H.I. Andtbacka, Kate Liu, Jason Chesney
Publikováno v:
EBioMedicine
Background Talimogene laherparepvec (T-VEC) is an intralesionally delivered, modified herpes simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission of T-VEC was systematically evaluated during and afte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bf631a1562a8e99d64bb5936506ecb3
https://pubmed.ncbi.nlm.nih.gov/31420301
https://pubmed.ncbi.nlm.nih.gov/31420301
Autor:
Merrick I. Ross, Howard L. Kaufman, Keith A. Delman, Frances A. Collichio, Mohammed M. Milhem, Thomas Amatruda, Jonathan S. Zager, Lisa Chen, Igor Puzanov, Mark Shilkrut, Robert H.I. Andtbacka, Lee D. Cranmer, Eddy C. Hsueh
Publikováno v:
Annals of Surgical Oncology
Purpose Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1b08bc06d34514a51519b81eec7ed9
http://europepmc.org/articles/PMC5090012
http://europepmc.org/articles/PMC5090012
Autor:
Robert O. Dillman, Cristina de Leon, Lee S. Schwartzberg, Khosrow Mahdavi, Carol DePriest, Edward F. McClay, Neil M. Barth, Robin E. Ellis, Thomas Amatruda
Publikováno v:
Cancer Biotherapy & Radiopharmaceuticals
In patients with metastatic melanoma, sequential single-arm and randomized phase II trials with a therapeutic vaccine consisting of autologous dendritic cells (DCs) loaded with antigens from self-renewing, proliferating, irradiated autologous tumor c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dd37bcfe993d776da38d6e54a63c25d
https://doi.org/10.1089/cbr.2015.1843
https://doi.org/10.1089/cbr.2015.1843
Autor:
Eric D. Whitman, Nicolas Batty, Sanjay Awasthi, John Nemunaitis, Christopher Windham, Jose Lutzky, Thomas Amatruda, Gerald Downey, Laura F. Hutchins, Jason Chesney, Russell E. Brown, Brendan D. Curti, Pierre L. Triozzi, Marcus C.B. Tan, Gerald P. Linette
Publikováno v:
Melanoma research. 28(1)
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We aim t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3dbcecc18776f023bdcc5b202339e8
https://pubmed.ncbi.nlm.nih.gov/29176501
https://pubmed.ncbi.nlm.nih.gov/29176501